For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Toray Rolls Out Remitch OD Tablets in South Korea
January 17, 2023
- Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Estimated 11,867 Patients Given Xocova as of Jan. 5: Shionogi
January 16, 2023
- Ono, Monash University Ink GPCR Antibody Deal
January 16, 2023
- Skyrizi’s New IV Form Now Available for Crohn’s Disease
January 16, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- Takeda’s Exkivity Approved in China for EGFR Exon 20+ NSCLC
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
- Zeria’s Acinon Now Sole Nizatidine Product Being Shipped as Yoshindo Launches Recall
January 13, 2023
- Janssen Vows to Offer New Positions for Employees Shown Exit Door: 1st Labor Talks
January 13, 2023
- Ferring to Take Over Gonax’s Japan Authorization from Astellas
January 13, 2023
- Xofluza Adds Pediatric Indication in Europe: Roche
January 13, 2023
- Alfresa Sets Up Regenerative Medicine Unit to Supply Master Cells, Eyes Distribution
January 12, 2023
- Kaken, Axcelead Hook Up on New Drug Discovery
January 12, 2023
- Mitsubishi Tanabe to End Sales of Lexapro as Deal Expires
January 12, 2023
- Takatsugu Den Tapped as Biogen Japan’s New President
January 12, 2023
- Opdivo Extends Best-Selling Streak to 12 Months: Encise
January 12, 2023
- Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
- Kaken Snags Japan Rights to CymaBay Med for Primary Biliary Cholangitis
January 11, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…